Is Summit Therapeutics a Millionaire Maker?

Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (NASDAQ: SMMT). The drugmaker's shares are up by nearly 540%, thanks to excellent clinical progress for its leading pipeline candidate, ivonescimab, a cancer treatment in development.The drug's prospects look so attractive that, despite Summit's $15 billion market cap -- an exceedingly rare feat for a drugmaker without a single product on the market -- some investors and analysts think it has substantial upside left.With that as a backdrop, let's find out whether Summit Therapeutics could deliver life-changing returns and help investors become millionaires.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool